4D Molecular Therapeutics (FDMT)

• Market cap: $260M
• 1 day: -3.10%
• 5 days: -4.90%
• 1 month: -24.93%
• 3 months: -48.63%
• 6 months: -73.20%
• Year to date: -73.51%
• 1 year: -73.51%
• 5 years: -86.10%
• 10 years: -86.10%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Employees: 201

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

38% more call options, than puts

Call options by funds: $1.66M | Put options by funds: $1.21M

27% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 44

2.7% less ownership

Funds ownership: 113.73% [Q2] → 111.03% (-2.7%) [Q3]

3% less funds holding

Funds holding: 143 [Q2] → 139 (-4) [Q3]

15% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 26

49% less capital invested

Capital invested by funds: $1.23B [Q2] → $624M (-$610M) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 42% upside
• Avg. target: $34 497% upside
• High target: $46 717% upside

5 analyst ratings

• positive: 4 80%
• neutral: 0 0%
• negative: 1 20%

B of A Securities Tazeen Ahmad 31% 1-year accuracy 9 / 29 met price target	717% upside $46	Buy Maintained	18 Dec 2024
Morgan Stanley Judah Frommer 38% 1-year accuracy 3 / 8 met price target	42% upside $8	Underweight Initiated	21 Nov 2024
Chardan Capital Geulah Livshits 15% 1-year accuracy 7 / 48 met price target	593% upside $39	Buy Maintained	14 Nov 2024
HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 12 / 50 met price target	539% upside $36	Buy Reiterated	14 Nov 2024
RBC Capital Luca Issi 23% 1-year accuracy 13 / 56 met price target	593% upside $39	Outperform Maintained	14 Nov 2024